申请人:WALTON S.A.
公开号:EP0302699A2
公开(公告)日:1989-02-08
Compounds of the general formula:
wherein R¹ represents hydrogen, a C₁₋₆ alkyl group or an acetyl group;
R² represents halogen;
R³ represents a group of the formula:
wherein R⁵ represents hydrogen or a phenyl or non-aromatic cyclic ether group and n is 2 or 3;
R⁴ represents a C₃₋₆ cycloalkyl, cyclohexenyl, C₁₋₆ alkoxy, trifluoromethyl, tetrahydrofuryl, 1,3-dioxolanyl or phenoxy group;
m is 0, 1, 2, 3 or 4 with the proviso that when m is 0, R⁴ is only a C₃₋₆ cycloalkyl or tetrahydrofuryl group;
and pharmacologically acceptable acid addition salts, quaternary ammonium salts and N-oxides thereof have pharmacological properties rendering them useful as antiematic agents with reduced undesirable side-effects. Various methods are described for their preparation involving formation of the amide link, etherification of the 2-hydroxy derivative, introducing the R⁵CH₂ group on the N-unsubstituted azabicyclooctane or nonane or, for 4-amino compounds, by hydrolysing a 4-acylamino derivative.
通式如下的化合物
其中 R¹ 代表氢、C₁₋₆ 烷基或乙酰基;
R² 代表卤素
R³ 代表式中的一个基团:
其中 R⁵ 代表氢或苯基或非芳香族环醚基团,n 为 2 或 3;
R⁴ 代表 C₃₋₆ 环烷基、环己烯基、C₁₋₆ 烷氧基、三氟甲基、四氢糠基、1,3-二氧戊环或苯氧基;
m 为 0、1、2、3 或 4,但当 m 为 0 时,R⁴ 仅为 C₃₋₆环烷基或四氢呋喃基;
以及药理学上可接受的酸加成盐、季铵盐及其 N-氧化物具有药理学特性,可用作抗呕吐剂,减少不良副作用。这些化合物的制备方法多种多样,包括酰胺链的形成、2-羟基衍生物的醚化、在 N-未取代的氮杂环辛烷或壬烷上引入 R⁵CH₂ 基团,或者对于 4-氨基化合物,通过水解 4-酰氨基衍生物。